UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6 11 16 18 L1 virus-like particle vaccine through 5 years of follow-up

British journal of cancer, 2006-12, Vol.95 (11), p.1459-1466

2006

Volltextzugriff (PDF)

Inactivation of Human Immunodeficiency Virus Type 1 Infectivity with Preservation of Conformational and Functional Integrity of Virion Surface Proteins

Journal of Virology, 1998-10, Vol.72 (10), p.7992-8001

1998

Volltextzugriff (PDF)

Differential Incorporation of CD45, CD80 (B7-1), CD86 (B7-2), and Major Histocompatibility Complex Class I and II Molecules into Human Immunodeficiency Virus Type 1 Virions and Microvesicles: Implications for Viral Pathogenesis and Immune Regulation

Journal of Virology, 2001-07, Vol.75 (13), p.6173-6182

2001

Volltextzugriff (PDF)

The impact of a quadrivalent human papillomavirus (types 6, 11, 16, 18) virus-like particle vaccine in European women aged 16 to 24

Journal of the European Academy of Dermatology and Venereology, 2009-10, Vol.23 (10), p.1147-1155

2009

Volltextzugriff (PDF)

Partial Activation and Induction of Apoptosis in CD4+ and CD8+ T Lymphocytes by Conformationally Authentic Noninfectious Human Immunodeficiency Virus Type 1

Journal of Virology, 2001-02, Vol.75 (3), p.1152-1164

2001

Volltextzugriff (PDF)

Distinct T cell receptor signaling requirements for perforin- or FasL-mediated cytotoxicity

The Journal of experimental medicine, 1996-04, Vol.183 (4), p.1697-1706

1996

Volltextzugriff (PDF)

Chemical inactivation of retroviral infectivity by targeting nucleocapsid protein zinc fingers: a candidate SIV vaccine

AIDS research and human retroviruses, 1998-10, Vol.14 Suppl 3, p.S311-S319

1998

Volltextzugriff (PDF)

Partial activation of CD8 + T cells by a self-derived peptide

Nature (London), 1995-11, Vol.378 (6554), p.295-298

1995

Volltextzugriff (PDF)

A novel chemistry for conjugating pneumococcal polysaccharides to Luminex microspheres

Journal of immunological methods, 2006-02, Vol.309 (1), p.75-85

2006

Volltextzugriff (PDF)

Memory T cells and vaccines

Vaccine, 2003-01, Vol.21 (5), p.419-430

2003

Volltextzugriff (PDF)

Priming of Human Papillomavirus Type 11-Specific Humoral and Cellular Immune Responses in College-Aged Women with a Virus-Like Particle Vaccine

Journal of Virology, 2002-08, Vol.76 (15), p.7832-7842

2002

Volltextzugriff (PDF)

Cyanovirin-N Binds to gp120 To Interfere with CD4-Dependent Human Immunodeficiency Virus Type 1 Virion Binding, Fusion, and Infectivity but Does Not Affect the CD4 Binding Site on gp120 or Soluble CD4-Induced Conformational Changes in gp120

Journal of Virology, 1999-05, Vol.73 (5), p.4360-4371

1999

Volltextzugriff (PDF)

Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old

Journal of acquired immune deficiency syndromes (1999), 2010-10, Vol.55 (2), p.197-204

2010

Volltextzugriff (PDF)

Analysis of the HIV-1 gp41 specific immune response using a multiplexed antibody detection assay

Journal of immunological methods, 2004-04, Vol.287 (1), p.49-65

2004

Volltextzugriff (PDF)

Ca2+ signaling modulates cytolytic T lymphocyte effector functions

The Journal of experimental medicine, 1998-04, Vol.187 (7), p.1057-1067

1998

Volltextzugriff (PDF)

Impact of Baseline Covariates on the Immunogenicity of a Quadrivalent (Types 6, 11, 16, and 18) Human Papillomavirus Virus-Like-Particle Vaccine

The Journal of infectious diseases, 2007-10, Vol.196 (8), p.1153-1162

2007

Volltextzugriff (PDF)

Population Seroprevalence of Human Papillomavirus Types 6, 11, 16, and 18 in Men, Women, and Children in Australia

Clinical infectious diseases, 2008-06, Vol.46 (11), p.1647-1655

2008

Volltextzugriff (PDF)

Simultaneous Quantitation of Antibodies to Neutralizing Epitopes on Virus-Like Particles for Human Papillomavirus Types 6, 11, 16, and 18 by a Multiplexed Luminex Assay

Clinical and Diagnostic Laboratory Immunology, 2003-01, Vol.10 (1), p.108-115

2003

Volltextzugriff (PDF)

IL-2 induces Fas ligand/Fas (CD95L/CD95) cytotoxicity in CD8+ and CD4+ T lymphocyte clones

The Journal of immunology (1950), 1997-06, Vol.158 (12), p.5612-5618

1997

Volltextzugriff (PDF)

Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19

The New England journal of medicine, 2022-06, Vol.386 (23), p.2188-2200

2022

Volltextzugriff (PDF)

C26 TREATMENT OF RESPIRATORY INFECTIONS: Pharmacokinetics And Pharmacodynamics Of Medi4893, An Investigational Anti-Staphylococcus Aureus Alpha Toxin Human Monoclonal Antibody, In Healthy Adults: A Phase 1, Randomised Placebo-Controlled Study

American journal of respiratory and critical care medicine, 2015-01, Vol.191, p.1

2015

Volltextzugriff (PDF)

Optimization and Validation of a Multiplexed Luminex Assay To Quantify Antibodies to Neutralizing Epitopes on Human Papillomaviruses 6, 11, 16, and 18

Clinical and Diagnostic Laboratory Immunology, 2005-08, Vol.12 (8), p.959-969

2005

Volltextzugriff (PDF)

1 – 25 von 2.553

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(2.159)
Mit Volltextzugriff
(2.092)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(16)
... seit 30 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6 11 16 18 L1 virus-like particle vaccine through 5 years of follow-up

Inactivation of Human Immunodeficiency Virus Type 1 Infectivity with Preservation of Conformational and Functional Integrity of Virion Surface Proteins

Differential Incorporation of CD45, CD80 (B7-1), CD86 (B7-2), and Major Histocompatibility Complex Class I and II Molecules into Human Immunodeficiency Virus Type 1 Virions and Microvesicles: Implications for Viral Pathogenesis and Immune Regulation

The impact of a quadrivalent human papillomavirus (types 6, 11, 16, 18) virus-like particle vaccine in European women aged 16 to 24

Partial Activation and Induction of Apoptosis in CD4+ and CD8+ T Lymphocytes by Conformationally Authentic Noninfectious Human Immunodeficiency Virus Type 1

Distinct T cell receptor signaling requirements for perforin- or FasL-mediated cytotoxicity

Chemical inactivation of retroviral infectivity by targeting nucleocapsid protein zinc fingers: a candidate SIV vaccine

Partial activation of CD8 + T cells by a self-derived peptide

A novel chemistry for conjugating pneumococcal polysaccharides to Luminex microspheres

Memory T cells and vaccines

Priming of Human Papillomavirus Type 11-Specific Humoral and Cellular Immune Responses in College-Aged Women with a Virus-Like Particle Vaccine

Cyanovirin-N Binds to gp120 To Interfere with CD4-Dependent Human Immunodeficiency Virus Type 1 Virion Binding, Fusion, and Infectivity but Does Not Affect the CD4 Binding Site on gp120 or Soluble CD4-Induced Conformational Changes in gp120

Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old

Analysis of the HIV-1 gp41 specific immune response using a multiplexed antibody detection assay

Ca2+ signaling modulates cytolytic T lymphocyte effector functions

Impact of Baseline Covariates on the Immunogenicity of a Quadrivalent (Types 6, 11, 16, and 18) Human Papillomavirus Virus-Like-Particle Vaccine

Population Seroprevalence of Human Papillomavirus Types 6, 11, 16, and 18 in Men, Women, and Children in Australia

Simultaneous Quantitation of Antibodies to Neutralizing Epitopes on Virus-Like Particles for Human Papillomavirus Types 6, 11, 16, and 18 by a Multiplexed Luminex Assay

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

IL-2 induces Fas ligand/Fas (CD95L/CD95) cytotoxicity in CD8+ and CD4+ T lymphocyte clones

Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19

C26 TREATMENT OF RESPIRATORY INFECTIONS: Pharmacokinetics And Pharmacodynamics Of Medi4893, An Investigational Anti-Staphylococcus Aureus Alpha Toxin Human Monoclonal Antibody, In Healthy Adults: A Phase 1, Randomised Placebo-Controlled Study

Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine

Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18

Optimization and Validation of a Multiplexed Luminex Assay To Quantify Antibodies to Neutralizing Epitopes on Human Papillomaviruses 6, 11, 16, and 18

Suchergebnisse filtern